Literature DB >> 18032540

Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.

G S Metsios1, A Stavropoulos-Kalinoglou, K M J Douglas, Y Koutedakis, A M Nevill, V F Panoulas, M Kita, G D Kitas.   

Abstract

OBJECTIVES: Rheumatoid arthritis (RA) is accompanied by increased resting energy expenditure (REE) and decreased fat-free mass (FFM). This is referred to as rheumatoid cachexia and is attributed to high levels of tumour necrosis factor-alpha (TNF-alpha). This study aimed to investigate the effects of anti-TNF-alpha therapy on REE, body composition, physical activity and protein intake in RA patients.
METHODS: Twenty RA patients [50% female; age: (mean +/- s.d.) 61.1 +/- 6.8 yrs; body mass index (BMI): 28.3 +/- 3.7 kg/m2] and 12 age-sex-BMI-matched healthy controls were assessed. REE (indirect calorimetry), body composition (bioelectrical impedance), the International Physical Activity Questionnaire (IPAQ), diet, Health Assessment Questionnaire (HAQ), disease activity [disease activity score 28 (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein] and serum TNF-alpha were measured before (Baseline) as well as 2 weeks (Time-1) and 12 weeks (Time-2) after initiation of anti-TNF-alpha treatment. Controls were only assessed at Baseline.
RESULTS: RA patients had significantly higher REE than controls at Baseline (1799.4 +/- 292.0 vs 1502.9 +/- 114.5 kcal/day, P = 0.002). Within the RA group, REE increased significantly between Time-1 and Time-2 (P = 0.001) but not between Baseline and Time-2. Sustained significant increases were observed in IPAQ (P = 0.001) and protein intake (P = 0.001). There were no significant changes in FFM or body fat. ESR (P = 0.002), DAS28 (P < 0.001), HAQ (P < 0.001) and TNF-alpha (P = 0.024) improved significantly. Physical activity (P = 0.001) and protein intake (P = 0.024) were significant between-subject factors for the elevation of REE.
CONCLUSIONS: After 12 weeks of anti-TNF-alpha therapy, there were significant improvements in disease activity and physical function, as well as physical activity and protein intake, but no significant changes in REE or FFM. There is a need for longer-term studies in this field.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032540     DOI: 10.1093/rheumatology/kem291

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  43 in total

1.  The role of nitric oxide during healing of trauma to the skeletal muscle.

Authors:  Lidiane Isabel Filippin; María José Cuevas; Elena Lima; Norma Possa Marroni; Javier Gonzalez-Gallego; Ricardo Machado Xavier
Journal:  Inflamm Res       Date:  2010-11-13       Impact factor: 4.575

Review 2.  Rheumatoid cachexia and cardiovascular disease.

Authors:  Gregory D Summers; Giorgos S Metsios; Antonios Stavropoulos-Kalinoglou; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2010-07-20       Impact factor: 20.543

3.  Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis.

Authors:  Rachel A Brown; Domenico Spina; Sayqa Butt; Gregory D Summers
Journal:  Clin Rheumatol       Date:  2011-10-19       Impact factor: 2.980

4.  Skeletal muscle stem cell characteristics and myonuclei content in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Rasmus Jentoft Boutrup; Jean Farup; Kristian Vissing; Michael Kjaer; Ulla Ramer Mikkelsen
Journal:  Rheumatol Int       Date:  2018-04-12       Impact factor: 2.631

5.  TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study.

Authors:  Éric Toussirot; Laurent Mourot; Barbara Dehecq; Daniel Wendling; Émilie Grandclément; Gilles Dumoulin
Journal:  Eur J Nutr       Date:  2013-10-31       Impact factor: 5.614

Review 6.  Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.

Authors:  Eun Ha Kang; Katherine P Liao; Seoyoung C Kim
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

Review 7.  Rheumatoid arthritis and metabolic syndrome.

Authors:  György Kerekes; Michael T Nurmohamed; Miguel A González-Gay; Ildikó Seres; György Paragh; Zsófia Kardos; Zsuzsa Baráth; László Tamási; Pál Soltész; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2014-08-05       Impact factor: 20.543

8.  Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months.

Authors:  Inga-Lill Engvall; Birgitta Tengstrand; Kerstin Brismar; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2010-10-21       Impact factor: 5.156

9.  Rheumatoid cachexia: a complication of rheumatoid arthritis moves into the 21st century.

Authors:  Ronenn Roubenoff
Journal:  Arthritis Res Ther       Date:  2009-04-27       Impact factor: 5.156

10.  Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Karen M J Douglas; Helen R Griffiths; George D Kitas
Journal:  Arthritis Res Ther       Date:  2008-12-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.